MENSA

Mensa Therapeutics is a biotechnology company dedicated to the discovery of novel therapeutic targets within the human secretome, which they refer to as the 'Mensa.' The company's proprietary platform enables the identification of secreted proteins that play pivotal roles in disease but have remained largely uncharacterized by traditional drug discovery methods. Mensa focuses on developing first-in-class biologics, particularly monoclonal antibodies, to modulate these targets in areas of high unmet need such as immunology and oncology. A spin-out from the University of Oxford, the company is supported by Oxford Science Enterprises and leverages deep expertise in T-cell biology and protein biochemistry to unlock a vast and largely untapped class of extracellular drug targets.